Clinical Trial Update: Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing HLX02 to Herceptin in previously untreated HER2-positive metastatic breast cancer has completed, and results have been posted. The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• HLX02 (trastuzumab biosimilar)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2024-05-17